Skip to main content
Caplight Logo









Artivila Biopharma

Artivila Biopharma

Private
ShenzhenHealthcare & Life Scienceshttps://artivila.com/

Last Round

Series A

Jun 25, 2026

Total Funding Raised

$35.7M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Artivila Biopharma is a biotechnology company that develops innovative drugs for autoimmune diseases, neurodegenerative diseases, and oncology using an AI-driven drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoveryAIDDsmall molecule therapeuticsautoimmune diseasebiotechCADDclinical-stage biopharmaAI drug discoverydrug developmenttherapeutic pipelinein silico drug designclinical trialsbiotech startupdrug licensingcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Artivila Biopharma Comparables

Compare Artivila Biopharma with similar companies based on industry and business-model similarity.

Artivila Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MindRank
83%
Terray Therapeutics
79%
Genesis Molecular AI
79%

Artivila Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 25, 2026
VC RoundMar 31, 2022
SeedMar 30, 2021
AngelNov 1, 2019

Artivila Biopharma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2026

    $13M round led by Green Pine Capital Partners

  • Sep 22, 2025

    Successful completion of Phase I study for ARD-885, a novel small molecule drug.

Recent news

Latest coverage and updates

  • receives_financingJun 25, 2026

    Artivila received financing of $55M in cumulative funding on Jun 25th '26.

  • receives_financingJun 25, 2026

    Artivila received financing of $12.8M in Series A on Jun 25th '26.

Artivila Biopharma Filings

Explore SEC and related filing metadata, where available.

Artivila Biopharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Artivila Biopharma's valuation, stock price, and market status.

Is Artivila Biopharma a public or private company?

Artivila Biopharma is a private company.

What is the current stock price of Artivila Biopharma?

Artivila Biopharma is a private company with no public stock price. No recent secondary market data is available.

How much is Artivila Biopharma worth (valuation)?

Valuation information for Artivila Biopharma is not publicly available.

Can I buy Artivila Biopharma stock?

Artivila Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Artivila Biopharma's last funding round?

Artivila Biopharma's most recent funding round was Series A on June 25, 2026.

Who are the main investors in Artivila Biopharma?

Key investors in Artivila Biopharma include HighLight Capital, 松禾资本 (Green Pine Capital Partners).

Will Artivila Biopharma IPO soon?

No public IPO plans have been announced for Artivila Biopharma.

How can I track Artivila Biopharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Artivila Biopharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShenzhen
Employee Range5
Year Founded2018
Last FundingJun 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?